Navitoclax Combo Significantly Reduces Spleen Volume in Myelofibrosis.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 70
- Publication type:
- Article
Works matching IS 08909091 AND DT 2024 AND VI 38 AND IP 2
Results: 10
1
2
Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 82
- By:
- Publication type:
- Article
3
Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 71
- By:
- Publication type:
- Article
4
Ibrutinib/Venetoclax Combo Shows PFS, OS Benefit as MRD-Guided Regimen in Frontline CLL.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 70
- Publication type:
- Article
5
Tafasitamab Quadruplet Appears Safe, Feasible in Newly Diagnosed DLBCL.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 69
- Publication type:
- Article
6
Reduced-Dose Talquetamab Yields Responses, Safety in R/R Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 69
- Publication type:
- Article
7
Key Takeaways From ASH 2023: Emerging Trends in Hematologic Oncology.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 45
- By:
- Publication type:
- Article
8
T-DM1/Tucatinib Improves PFS vs Placebo in HER2+ Metastatic Breast Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 68
- Publication type:
- Article
9
Dato-DXd Improves PFS vs Chemo in HR+/HER2-- Metastatic Breast Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 68
- Publication type:
- Article
10
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma: Report of the Lymphoma Research Foundation's 2023 Mantle Cell Lymphoma Scientific Consortium and Workshop.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 2, p. 51, doi. 10.46883/2024.25921013
- Publication type:
- Article